Clinical Trial Update: AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib [Phase 2]

View source ↗

Summary

Phase 2 open-label study of AMG 386 combined with sunitinib in first-line or post-cytokine advanced renal cell carcinoma; study completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AMG-386 (trebananib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Amgen | Conditions: Advanced Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-01